Difference between revisions of "Team:Central Calgary/project"
Line 96: | Line 96: | ||
<div class="container-fluid" id="ourVision" style="text-align:justify;"> | <div class="container-fluid" id="ourVision" style="text-align:justify;"> | ||
<h1 style="padding-left:1vw;"> Our Vision </h1> | <h1 style="padding-left:1vw;"> Our Vision </h1> | ||
− | <p style="padding: 0 4.16vw">Of the numerous treatments | + | <p style="padding: 0 4.16vw">Of the numerous cancer treatments available today, not one has the ability to ensure a cancer-free future for the patient. Many people feel that the drawbacks of cancer treatment are not worth enduring because of their serious side effects, even with the possibility of becoming relatively cancer free. |
− | In search of a more effective treatment | + | |
− | Antiangiogenic therapy is what many doctors are referring to as the future of cancer treatment (Grothley, Kozlaff & Rosen, 2007). Through numerous trials, doctors have found that with antiangiogenic therapy, tumours may be left permanently dormant without need for further treatment. Currently, there are | + | <br> |
+ | |||
+ | These side effects include hair loss, vomiting, as well as damage to the nervous system and vital organs, to name just a few (Canadian Cancer Society, 2015). People rendered weak by their cancer often experience severe complications post- cancer surgery (Mayo Clinic, 2015). | ||
+ | |||
+ | <br> | ||
+ | |||
+ | In search of a more effective treatment that does not harm healthy somatic cells, the Central iGEM team has considered taking a different approach. Aduro BioTech Inc. is a means of inspiration for this team. Aduro, an established biotech company, has been practicing similar preliminary work involving synthetic biology. Aduro has engineered Listeria to elicit an immune response so that endothelial cells are attacked (Aduro, 2015). | ||
+ | Antiangiogenic therapy is what many doctors are referring to as the future of cancer treatment (Grothley, Kozlaff & Rosen, 2007). | ||
+ | |||
+ | <br> | ||
+ | |||
+ | Through numerous trials (Grothley, Kozlaff, & Rosen, 2007), doctors have found that with antiangiogenic therapy, tumours may be left permanently dormant without need for further treatment. Currently, there are antiangiogenic drugs using Bevacizumab (BV) being prescribed to cancer patients, which are often used in combination with chemotherapy treatments (Grothley, Kozlaff & Rosen, 2007).. Studies (Grothley, Kozlaff & Rosen, 2007) have shown that antiangiogenic drugs improve progression-free survival and overall survival in cancer patients. This approach to antiangiogenic therapy, through the bacterial system of delivery, could potentially one day replace chemotherapy as the primary cancer treatment (Grothley, Kozlaff & Rosen, 2007). | ||
+ | |||
</p> | </p> | ||
</div> | </div> | ||
Line 114: | Line 126: | ||
</div> | </div> | ||
+ | <div class="container-fluid" id="future" style="text-align:justify;"> | ||
+ | <h1 style="padding-left:1vw;"> Future Directions</h1> | ||
+ | <p style="padding: 0 4.16vw"> Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future | ||
+ | </p> | ||
+ | </div> | ||
<script type="text/javascript" src="https://2015.igem.org/Team:Central_Calgary/bootstrapjs?action=raw&ctype=text/javascript"></script> | <script type="text/javascript" src="https://2015.igem.org/Team:Central_Calgary/bootstrapjs?action=raw&ctype=text/javascript"></script> |
Revision as of 01:37, 19 September 2015
Project
Our Vision
Of the numerous cancer treatments available today, not one has the ability to ensure a cancer-free future for the patient. Many people feel that the drawbacks of cancer treatment are not worth enduring because of their serious side effects, even with the possibility of becoming relatively cancer free.
These side effects include hair loss, vomiting, as well as damage to the nervous system and vital organs, to name just a few (Canadian Cancer Society, 2015). People rendered weak by their cancer often experience severe complications post- cancer surgery (Mayo Clinic, 2015).
In search of a more effective treatment that does not harm healthy somatic cells, the Central iGEM team has considered taking a different approach. Aduro BioTech Inc. is a means of inspiration for this team. Aduro, an established biotech company, has been practicing similar preliminary work involving synthetic biology. Aduro has engineered Listeria to elicit an immune response so that endothelial cells are attacked (Aduro, 2015).
Antiangiogenic therapy is what many doctors are referring to as the future of cancer treatment (Grothley, Kozlaff & Rosen, 2007).
Through numerous trials (Grothley, Kozlaff, & Rosen, 2007), doctors have found that with antiangiogenic therapy, tumours may be left permanently dormant without need for further treatment. Currently, there are antiangiogenic drugs using Bevacizumab (BV) being prescribed to cancer patients, which are often used in combination with chemotherapy treatments (Grothley, Kozlaff & Rosen, 2007).. Studies (Grothley, Kozlaff & Rosen, 2007) have shown that antiangiogenic drugs improve progression-free survival and overall survival in cancer patients. This approach to antiangiogenic therapy, through the bacterial system of delivery, could potentially one day replace chemotherapy as the primary cancer treatment (Grothley, Kozlaff & Rosen, 2007).
Our Construct
CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT CONSTRUCT
Accomplishments
ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP ACCOMP
Future Directions
Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future Future